Reports
Sale
Granulomatosis with Polyangiitis Treatment Market Share: By Drug Type: Steroids, Immunosuppressant, Others; By Route of Administration: Oral, Injectable, Others; By Mode of Purchase: Prescription, Over the Counter; By Gender: Male, Female; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Granulomatosis with Polyangiitis Treatment Market Size
The granulomatosis with polyangiitis treatment market is expected to grow at a CAGR of 4.90% during the forecast period of 2024-2032, driven by increased clinical trials and research to develop novel therapies and improve existing treatment options, enhanced disease recognition and management, and growing regulatory support across the 8 major markets.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Granulomatosis with Polyangiitis Treatment Market Outlook
- The incidence of granulomatosis with polyangiitis tends to increase with age, with a peak incidence in older adults occurring between the ages of 64 to 75 years. Thus, the growing aging population is expected to drive market demand for effective treatments.
- One of the major market trends is the surge in clinical research activities aimed at improving existing treatment protocols.
- The market share is influenced by the growing regulatory support. Incentives offered by the health regulatory bodies encourage pharmaceutical companies to invest in rare disease treatments including granulomatosis with polyangiitis.
Granulomatosis with Polyangiitis Treatment Market Overview
Granulomatosis with polyangiitis is a medical condition that causes inflammation of blood vessels. The body parts affected by this disease include ears, nose, and kidney, among others. This disease is prevalent among children, adults, and geriatrics and causes severe symptoms such as chest pain, tiredness, nosebleeds, loss of appetite, and weight loss.
The granulomatosis with polyangiitis treatment market is witnessing an increase in the research and development activities by major biopharmaceutical companies. Key market players are actively investing in developing effective therapeutics to counter this disorder which is likely to lead to improved medications. Moreover, the market is anticipated to be aided by advanced X-rays, CT scans, and MRI in modern hospitals which is bolstering the diagnosis process for timely treatment of this condition. Furthermore, the market is likely to be navigated by the increasing geriatric population, coupled with the favorable reimbursement policies of the government.
Granulomatosis with Polyangiitis Treatment Market Growth Drivers
Increasing Elderly Population to Affect the Market Landscape Significantly
The prevalence of this rare vasculitis affecting small vessels is estimated between 1/6,400 - 42,000 with the incidence ranging between 1/84,000-475,000 every year. Recent data reveals that childhood-onset disease shows female predominance whereas a slight male predominance characterizes adult-onset. Among the anti-neutrophil-cytoplasmic-antibody (ANCA) associated vasculitides (AAV), granulomatosis with polyangiitis is considered as the most common type. The incidence rate is reported to be higher in adults compared to the pediatric age group with a peak incidence at 64 to 75 years of age. Since the prevalence of this autoimmune disease tends to increase with age, the growing aging population is expected to influence the market demand for effective treatments.
Growth in Clinical Trials to Meet Rising Granulomatosis with Polyangiitis Treatment Market Demand
There is a growing number of clinical trials and research activities focused on exploring new treatment strategies and drug combinations to manage granulomatosis with polyangiitis. For instance, a study published in JAMA Network Open suggested that granulomatosis with polyangiitis patients, if treated with rituximab compared to cyclophosphamide for induction therapy, are more likely to show achievement of remission. Such findings are set to influence clinical decision-making and guidelines associated with the choice of remission-inducing regimen for patients with GPA. Thus, the surge in clinical research activities is anticipated to improve existing treatment protocols and augment market demand in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Granulomatosis with Polyangiitis Treatment Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Advancements in Diagnostic Techniques | The market is experiencing rising innovations in diagnostic techniques, such as high-resolution imaging and biomarkers, which are enabling earlier and more accurate diagnosis of granulomatosis with polyangiitis. Such advancements are increasing the diagnosis rates of the disorder which drives the demand for therapies. |
| Growing Regulatory Support | Health regulatory bodies such as the United States FDA and the European Medicines Agency (EMA) are offering incentives for the development of treatments for rare diseases, including granulomatosis with polyangiitis. These incentives may include orphan drug designation, which can comprise benefits like market exclusivity and tax credits. Such improvements in regulatory framework encourage pharmaceutical companies to invest in rare disease treatments, which is expected to boost the granulomatosis with polyangiitis treatment market share. |
| Strategic Partnerships and Collaborations | One of the major market trends is the increased strategic collaborations and partnerships among pharmaceutical companies in order to enhance their research capabilities and expand product portfolios. Such collaborations expedite the development of novel treatments and propel market growth. Moreover, the rise in collaborative efforts between academic institutions, pharmaceutical companies, and research organizations is expected to drive innovation in the market. |
| Use of Combination Therapies | There is a growing interest in combination therapies that involve treatment with multiple drugs to achieve better clinical outcomes. This approach aims to reduce relapse rates for patients with granulomatosis with polyangiitis and is likely to elevate the market value. For instance, it was reported that the combination of rituximab and methotrexate can be used as a salvage therapy in cases of persistently active granulomatosis with polyangiitis. |
Granulomatosis with Polyangiitis Treatment Segmentation
Market Breakup by Drug Type
- Steroids
- Prednisolone
- Dexamethasone
- Others
- Immunosuppressant
- Cyclosporine
- Tacrolimus
- Sirolimus
- Others
- Others
Market Breakup by Route of Administration
- Oral
- Injectable
- Others
Market Breakup by Mode of Purchase
- Prescription
- Over the Counter
Market Breakup by Gender
- Male
- Female
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Granulomatosis with Polyangiitis Treatment Market Share
Market Segmentation Based on Drug Type is Anticipated to Witness Substantial Growth
Based on the drug type, the market is segmented into steroids (prednisolone, dexamethasone, and others) and immunosuppressants (cyclosporine, tacrolimus, sirolimus), among others. Immunosuppressants for the treatment of granulomatosis with polyangiitis are gaining traction in the healthcare industry, owing to the high response rate of this medication. Immunosuppressants such as cyclophosphamide with prednisone are widely used in the treatment of this disease as they pose a lesser chance of fatality during the treatment.
Such immunosuppressants are consumed orally which is a major advantage of this medication amidst the changing patient preference towards minimally invasive treatment procedures. Methotrexate and azathioprine are some other examples of immunosuppressants that calm down the immune system of the body, thereby, keeping the disease under control. Therefore, the anticipated increase in the demand for immunosuppressants are likely to aid the segment’s growth in the coming years.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Granulomatosis with Polyangiitis Treatment Market Analysis by Region
The segmentation based on the region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. Countries such as the United States are high healthcare spenders globally. The regulations of the government encouraging the development of therapeutics and diffusing knowledge about this disorder are propelling the market growth. In addition to this, the growing FDA approvals of immunosuppressants and drugs are further expanding the opportunities for this treatment market.
Leading Players in the Granulomatosis with Polyangiitis Treatment Market
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Genentech, Inc. (A subsidiary of F. Hoffman-La Roche Ltd)
This American biotechnology corporation, operating as an independent subsidiary under its parent organization Roche Holding AG, is one of the leading market players. Its FDA-approved Rituxan® (rituximab) is commonly used to adult patients with granulomatosis with polyangiitis.
GlaxoSmithKline plc.
Global biopharma company GlaxoSmithKline plc. significantly contributes the granulomatosis with polyangiitis treatment market growth by investing heavily in R&D to bring new treatments for autoimmune diseases to market.
Teva Pharmaceutical Industries Ltd.
Israeli multinational pharmaceutical company Teva Pharmaceutical Industries Ltd. has a prominent presence in the market and is known for its TRUXIMA® (rituximab-abbs) injection, a biosimilar of Rituxan® (rituximab), for the treatment of granulomatosis with polyangiitis.
Pfizer Inc.
This global biopharmaceutical company is engaged in the development of innovative treatments for several autoimmune diseases. The key product of the company includes RUXIENCE® (rituximab-pvvr) injection which is indicated for granulomatosis with polyangiitis in adult patients in combination with glucocorticoids.
Other key players in the market include Actiza Pharma, Sun Pharmaceutical Industries Ltd., Janssen Pharmaceutical, Inc., Novartis AG, and Sanofi.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Mode of Purchase |
|
| Breakup by Gender |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Granulomatosis with Polyangiitis Treatment Market Report
- What was the granulomatosis with polyangiitis treatment market value in 2023?
- What is the granulomatosis with polyangiitis treatment market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on drug type?
- What is the market breakup based on the route of administration?
- What is the market breakup by mode of purchase?
- What is the market breakup based on gender?
- Who are the major end users in the market?
- What are the major distribution channels present in the market?
- What are the major factors aiding the granulomatosis with polyangiitis treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is projected to witness expedited growth during the forecast period?
- How does the prevalence and incidence of granulomatosis with polyangiitis affect the market landscape?
- What are the major granulomatosis with polyangiitis treatment market trends?
- Which drug type will dominate the market share?
- Which route of administration is expected to have a high market value in the coming years?
- Which mode of purchase will experience the elevated demand in the market segment?
- Which gender is poised to fuel the market demand?
- Which end user is projected to contribute to the highest market growth?
- Which distribution channel is anticipated to boost the market share?
- Who are the key players involved in the granulomatosis with polyangiitis treatment market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Granulomatosis with Polyangiitis Treatment Market Overview – 8 Major Markets
3.1 Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023)
3.2 Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
4 Granulomatosis with Polyangiitis Treatment Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Granulomatosis with Polyangiitis Treatment Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.1.1 Prevalence, by Country
6.1.1.1 U.S.
6.1.1.2 U.K.
6.1.1.3 EU4
6.1.1.4 India
6.1.1.5 Japan
6.1.2 Mortality, by Country
6.1.2.1 U.S.
6.1.2.2 U.K.
6.1.2.3 EU4
6.1.2.4 India
6.1.2.5 Japan
6.1.3 Treatment seeking rate, by Country
6.1.3.1 U.S.
6.1.3.2 U.K.
6.1.3.3 EU4
6.1.3.4 India
6.1.3.5 Japan
7 Granulomatosis with Polyangiitis Treatment Market Landscape – 8 Major Markets
7.1 Granulomatosis with Polyangiitis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Granulomatosis with Polyangiitis Treatment: Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Route of Administration
8 Granulomatosis with Polyangiitis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Granulomatosis with Polyangiitis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 PESTEL Analysis
10.3.1 Political
10.3.2 Economic
10.3.3 Social
10.3.4 Technological
10.3.5 Legal
10.3.6 Environment
10.4 Porter’s Five Forces Model
10.4.1 Bargaining Power of Suppliers
10.4.2 Bargaining Power of Buyers
10.4.3 Threat of New Entrants
10.4.4 Threat of Substitutes
10.4.5 Degree of Rivalry
10.5 Key Demand Indicators
10.6 Key Price Indicators
10.7 Industry Events, Initiatives, and Trends
10.8 Value Chain Analysis
11 Granulomatosis with Polyangiitis Treatment Market Segmentation (2017-2032) - 8 Major Markets
11.1 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type
11.1.1 Market Overview
11.1.2 Steroids
11.1.2.1 Prednisolone
11.1.2.2 Dexamethasone
11.1.2.3 Others
11.1.3 Immunosuppressant
11.1.3.1 Cyclosporine
11.1.3.2 Tacrolimus
11.1.3.3 Sirolimus
11.1.3.4 Others
11.1.4 Others
11.2 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Injectable
11.2.4 Others
11.3 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
11.3.1 Market Overview
11.3.2 Prescription
11.3.3 Over the Counter
11.4 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
11.4.1 Market Overview
11.4.2 Male
11.4.3 Female
11.5 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Home Healthcare
11.5.5 Others
11.6 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacies
11.6.3 Retail Pharmacies
11.6.4 Others
11.7 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
11.7.5 India
12 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032)
12.1 United States Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023)
12.2 United States Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
12.3 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type
12.3.1 Market Overview
12.3.2 Steroids
12.3.2.1 Prednisolone
12.3.2.2 Dexamethasone
12.3.2.3 Others
12.3.3 Immunosuppressant
12.3.3.1 Cyclosporine
12.3.3.2 Tacrolimus
12.3.3.3 Sirolimus
12.3.3.4 Others
12.3.4 Others
12.4 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
12.4.1 Market Overview
12.4.2 Oral
12.4.3 Injectable
12.4.4 Others
12.5 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
12.5.1 Market Overview
12.5.2 Prescription
12.5.3 Over the Counter
12.6 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
12.6.1 Market Overview
12.6.2 Male
12.6.3 Female
12.7 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
12.7.1 Market Overview
12.7.2 Hospitals
12.7.3 Specialty Clinics
12.7.4 Home Healthcare
12.7.5 Others
12.8 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
12.8.1 Market Overview
12.8.2 Hospital Pharmacies
12.8.3 Retail Pharmacies
12.8.4 Others
13 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032)
13.1 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type
13.3.1 Market Overview
13.3.2 Steroids
13.3.2.1 Prednisolone
13.3.2.2 Dexamethasone
13.3.3 Immunosuppressant
13.3.3.1 Cyclosporine
13.3.3.2 Tacrolimus
13.3.3.3 Sirolimus
13.3.4 Others
13.4 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
13.4.1 Market Overview
13.4.2 Oral
13.4.3 Injectable
13.4.4 Others
13.5 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
13.5.1 Market Overview
13.5.2 Prescription
13.5.3 Over the Counter
13.6 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
13.6.1 Market Overview
13.6.2 Male
13.6.3 Female
13.7 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
13.7.1 Market Overview
13.7.2 Hospitals
13.7.3 Specialty Clinics
13.7.4 Home Healthcare
13.7.5 Others
13.8 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
13.8.1 Market Overview
13.8.2 Hospital Pharmacies
13.8.3 Retail Pharmacies
13.8.4 Others
14 Japan Granulomatosis with Polyangiitis Treatment Market
14.1 Japan Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023)
14.2 Japan Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
14.3 Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type
14.3.1 Market Overview
14.3.2 Steroids
14.3.2.1 Prednisolone
14.3.2.2 Dexamethasone
14.3.2.3 Others
14.3.3 Immunosuppressant
14.3.3.1 Cyclosporine
14.3.3.2 Tacrolimus
14.3.3.3 Sirolimus
14.3.3.4 Others
14.3.4 Others
14.4 Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Injectable
14.4.4 Others
14.5 Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
14.5.1 Market Overview
14.5.2 Prescription
14.5.3 Over the Counter
14.6 Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
14.6.1 Market Overview
14.6.2 Male
14.6.3 Female
14.7 Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
14.7.1 Market Overview
14.7.2 Hospitals
14.7.3 Specialty Clinics
14.7.4 Home Healthcare
14.7.5 Others
14.8 Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
14.8.1 Market Overview
14.8.2 Hospital Pharmacies
14.8.3 Retail Pharmacies
14.8.4 Others
15 India Granulomatosis with Polyangiitis Treatment Market
15.1 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) Historical Value (2017-2023)
15.2 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) Forecast Value (2024-2032)
15.3 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type
15.3.1 Market Overview
15.3.2 Steroids
15.3.2.1 Prednisolone
15.3.2.2 Dexamethasone
15.3.2.3 Others
15.3.3 Immunosuppressant
15.3.3.1 Cyclosporine
15.3.3.2 Tacrolimus
15.3.3.3 Sirolimus
15.3.3.4 Others
15.3.4 Others
15.4 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Injectable
15.4.4 Others
15.5 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
15.5.1 Market Overview
15.5.2 Prescription
15.5.3 Over the Counter
15.6 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
15.6.1 Market Overview
15.6.2 Male
15.6.3 Female
15.7 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
15.7.1 Market Overview
15.7.2 Hospitals
15.7.3 Specialty Clinics
15.7.4 Home Healthcare
15.7.5 Others
15.8 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
15.8.1 Market Overview
15.8.2 Hospital Pharmacies
15.8.3 Retail Pharmacies
15.8.4 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Market Share by Top 5 Companies
22.2 Genentech, Inc. (A subsidiary of F. Hoffman-La Roche Ltd)
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 GlaxoSmithKline plc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Teva Pharmaceutical Industries Ltd.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Pfizer Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Actiza Pharma
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Sun Pharmaceutical Industries Ltd.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Janssen Pharmaceutical, Inc.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Novartis AG
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Sanofi
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
23 Granulomatosis with Polyangiitis Treatment Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER